Top10, the most valuable new drug research and development project in the field of biopharmaceuticals.

EP Vantage, a world-renowned life sciences industry market consulting firm, recently released a report analyzing the most valuable TOP10 drug research and development programs in the biopharmaceutical sector, and the following is a short answer to each drug. 1, Tirzepatide The drug is a large molecule peptide drug developed by Lilly, with the effect of gastric inhibitor polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) double receptor agonists.
both gIP and GLP-1 are both hormones secreted by the intestines that promote insulin secretion. Data released at this year's ADA conference
showthat the drug significantly reduces body weight and has improved gastrointestinal side effects in people with type 2 diabetes who effectively lower blood sugar.
, the drug also improves the NASH marker.
data from key SURPASS projects is expected to be released by the end of 2020.
Lilly also plans to promote another GIP/GLP/glucagon triple agonisant to Stage II next year.
rival Novo Nordisk is also developing a new drug for the mechanism, with Phase I data from NN1706 expected to be released soon.
from the available data, multireceptor agonists are more effective in reducing sugar and weight loss than simple GLP-1 agonists.
analysts point out that multi-target receptor agonists will be a focus in the diabetes field in 2020.
2, BMS-986165 The drug is a new, oral, selective TYK2 inhibitor developed by Baxter Squibb, its unique mechanism is different from other kinase inhibitors, the drug is currently in Phase III clinical, for the treatment of psoriasis and a variety of autoimmune diseases.
TYK2 is an intracellular signaling kinase that mediates cytokine-driven immune and pro-inflammatory signaling pathways that play a vital role in the chronic inflammatory cycle of immune-mediated diseases.
had to mention Otezla, another drug for the drug.
in late June, BMS decided to sell Otezla, which Aminsin took over in October for $13.2 billion, in an effort to pass U.S. antitrust reviews.
Otezla is considered a safer but less effective option for psoriasis, and BMS considers BMS-986165 to have a better business prospects.
, Pfizer and Johnson and Johnson are also developing TYK2 inhibitors, a new mechanism that autoimmune diseases will need to focus on in 2020.
3, TransCon hGH The drug is a long-acting human growth hormone (hGH) developed by Ascendis to treat child growth hormone deficiency (GHD), a disease caused by insufficient growth hormone secreted by the pituitary gland, who is not only short in size, but also has metabolic abnormalities, psychosocial challenges, cognitive impairments and poor quality of life.
for decades, the standard of care for GHD has been to inject hGH once a day to improve growth and metabolic effects.
for caregivers and patients, the daily injection is expensive, which leads to poor compliance and reduces overall treatment outcomes.
the drug, developed using TransCon technology, continuously releases unmodified growth hormone, which is the same as one hGH a day used in daily treatment, at a predictable rate for a week.
in Phase III clinical, the drug's subcutaneous administration is more effective than daily hGH (11.2cm/year vs 10.3cm/year, p-0.0088).
2018, Ascendis and Visan Capital jointly founded Vivision Pharmaceuticals to develop TransCon technology products in Greater China.
in October this year, TransCon hGH was approved by NMPA to launch Phase III clinical studies in China.
4, Bempegaldesleukin (NKTR-214, bempeg) This drug is an immunostimulant developed by Nektar Therapeutics, a CD122 bias IL-2 pathway agonisant that stimulates the proliferation of these anti-cancer immune cells by targeting natural killer cells (NK cell), CD4-T cells, CD8-T cells.
in previous clinical studies, NKTR-214 demonstrated the potential for multitype tumor treatment.
, Nektar has partnered with Pfizer/Merck, Baxter, Mercado, Lilly and other pharmaceutical companies to evaluate bempeg joint immunoosine checkpoint inhibitors for the treatment of a variety of solid tumors.
, bempeg in conjunction with Opdivo to treat melanoma, renal cell carcinoma has entered Phase III clinical, treatment of urinary skin cancer into Phase II clinical.
data released at the SITC's annual meeting in November, the total remission rate of peated melanoma in the first-line treatment of bempeg-Opdivo was 53%.
5, SAGE-217 The drug developed by Sage Therapeutics, which is a new generation of forward-to-do-the-conformation regulator, the regulation of the central nervous system is of great significance gabA receptors with better selectivity, the current treatment of postpartum depression (PDD), severe depression, refractory depression, severe depression combined insomnia has entered Phase III clinical.
in early December, the failure of SAGE-217, a Phase III clinical study to treat severe depression, wiped out billions of dollars in the company's market value.
, however, industry analysts remain confident that the drug will treat other indications, particularly PDD.
in March, Sage's drug Zulresso was approved by the U.S. FDA, making it the first and only drug approved for PDD.
However, Zulresso is administered intravenously, SAGE-217 is administered orally, and if available, will further consolidate Sage's dominance in the PDD field.
6, Tezepelumab The drug was developed by Amgen, is a pioneering anti-TSLP monotonica, is currently in Phase III clinical treatment of asthma.
TSLP is an epithelial cytokine produced against inflammatory stimuli that plays a key role in the occurrence and persistence of airway inflammation.
TSLP drives the release of downstream T2 cytokines and activates multiple types of cells involved in non-T2-driven inflammation.
TSLP has been identified as an important target for the treatment of widespread asthma due to early upstream activities involved in inflammatory cascade reactions.
blocking TSLP prevents immune cells from releasing pro-inflammatory cytokines, preventing asthma from worsening and improving asthma control.
currently available, listed asthma biologics are only available for certain types of asthma (i.e. subgroup patients), such as eosinophilic asthma.
tezepelumab specifically binds to human TSLP and blocks its interaction with receptor complexes, and due to its effect on the early upstream of inflammatory cascade reactions, the drug has the potential to be used in a wide range of patients with severe uncontrolled asthma, regardless of patient phenotype or T2 biomarker status.
previously, the drug has been approved by the FDA as a breakthrough drug.
if it goes on the market, the drug will treat a much larger population than existing asthma biologics.
7, Mirikizumab, developed by Lilly, a human-derived IgG4 monoclonal antibody, targeted in combination with IL-23 p19 sub-cells, developed for the treatment of a variety of immune diseases;
currently available, there are a number of IL-23 inhibitors on the market, including Johnson and Johnson Stelara and Tremfya, Sun Pharmaceuticals Ilumya, and AbbVie Skyrizi.
of these four drugs, only Stelara has been approved for Crohn's disease.
analysts believe that mirikizumab has the potential to become the 5th IL-23 inhibitor in the market for psoriasis.
but the drug has a greater chance of overstepping in the area of immune intestinal diseases, including Crohn's disease and ulcerative colitis, which will also be an important disease area developed by Lilly.
8, mRNA-2752 The drug was developed by the biotech company Unicorn Moderna, an innovative mRNA therapy that transforms immuno-reactive "cold" tumors into "hot" tumors.
mRNA-2752 is administered by local (intra-tumor) injection, which encodes three immunomodulators, including two secreted cytokines IL-23 and IL36, and a T-cell receptor membrane binding co-stimulating molecule OX40L.
the drug can produce high concentrations of immunomodulators around the tumor, alter the microenvironment of "cold" tumors, induce a wide range of immune responses, and promote the elimination of injection sites and distant tumors.
, although currently clinical in phase I, some bold analysts have begun to paint a broad picture of the drug.
in particular, the drug is the only drug in the TOP10 asset that is clinically developed in Stage I.
by 2020, Moderna will release clinical data that will help provide a clearer picture of the drug's future.
9, Efgartigimod, the industry-leading anti-FcRn project, developed by Belgian pharmaceutical company Argenx, is the first anti-FcRn antibody fragment, developed using ABDEG technology, targeting the combination of IgG recycling receptor FcRn to prevent IgG recovery, thus enabling IgG to deplete faster and promote IgG removal.
currently, the drug has been developed to treat a variety of severe autoimmune diseases mediated by high-level pathogenic IgG, such as severe muscle weakness (MG), immunoplatelet reduction (ITP), common herpes (PV), and chronic inflammatory demyelinion-induced neuropathy.
, the treatment of severe muscle weakness (MG) has entered Phase III clinical.
in Phase II clinical trials, efgartigimod treatment MG, ITP, PV have achieved very good efficacy data.
note, efgartigimod topped the list with a net present value of $6.4 billion in the 15 most valuable new drug development assets of 2018.
in November, Argenx raised $550 million by offering 4.6 million common shares.
seems to mean that the company is determined to move on its own in the development of efgartigimod.
10, RG7828 RG7828 (mosunetuzumab) is a human-derived full-length T-cell-dependent dual-specific antibody that targets CD20 and CD3 on B cells, a dual target that activates and redirects T cells in patients and eliminates target B cells by releasing toxic proteins into B cells.
currently, the drug is in Phase II clinical development for the treatment of a variety of blood system malignancies.
at ash's annual meeting in December, mosunetuzumab became the focus of industry attention - a strong, lasting remission in patients with poor prognosis recurrence or refractive B-cell non-Hodgkin's lymphoma (R/R B-NHL), including patients who relapsed after CAR-T therapy.
this is a real and significant development that threatens the more complex cell therapy being developed.
data showed that in inert NHL patients and invasive NHL patients, the total remission rate (ORR) was 62.7%, 37.1%, and the total remission rate (CR) was 43.3% and 19.4%, respectively, while the ORR was 38.9% and CR was 22.2% in patients receiving CAR-T cell therapy.
Reference Source: Ones to Watch: Biopharma's Most Valuable R and D Projects.